[Skip to Navigation]
Sign In
Views 1,079
Citations 0
Invited Commentary
June 3, 2021

Biomarkers in Nonmetastatic Castrate-Resistant Prostate Cancer: A Step in the Right Direction

Author Affiliations
  • 1Harvard Radiation Oncology Program, Boston, Massachusetts
  • 2Department of Radiation Oncology, University of Miami, Miami, Florida
  • 3Department of Radiation Oncology, Memorial Sloan Kettering Cancer, New York, New York
JAMA Oncol. 2021;7(7):1014-1015. doi:10.1001/jamaoncol.2021.1358

Three recent landmark trials have redefined the standard of care for patients with nonmetastatic, castrate-resistant prostate cancer (nmCRPC).1-4 These trials demonstrate that for men with nmCRPC and a prostate-specific antigen doubling time of 10 months or fewer, the addition of a second-generation androgen signaling inhibitor (ASI) to androgen deprivation therapy (ADT) prolongs not only metastasis-free survival (MFS) but also overall survival.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words